163222-33-1

Basic information

• Product Name: Ezetimibe
• Synonyms: (3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)azetidin-2-one;Ticagrelor and its interMediate;Ezetimibe 1-(4-Fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxy-propyl]-4-(4-hydroxyphenyl)-azetidin-2-one;Ezatimibe;zetia/vytorin;SCH 60969;Ezetimibe, >=99%;(3R,4S)-1-(4-Fluorophenyl)-3-((S)-3-(4-fluorophenyl)-3-hydroxypropyl)-4-(4-hydroxyphenyl)azeti
• CAS NO: 163222-33-1
• Molecular Formula: C₂₄H₂₁F₂NO₃
• Molecular Weight: 409.43
• EINECS: 1308068-626-2
• Product Categories: Final material;API;Isotope;CEDAX;Cardiovascular APIs;Ezetimibe;All Inhibitors;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 163222-33-1.mol
• Article Data: 70

Chemical Properties

• Melting Point: 164-166°C
• Boiling Point: 654.9 °C at 760 mmHg
• Flash Point: 349.9 °C
• Appearance: white powder
• Density: 1.334 g/cm³
• Vapor Pressure: 4.83E-18mmHg at 25°C
• Refractive Index: 1.623
• Storage Temp.: -20?C Freezer
• Solubility: Soluble in DMSO (up to 25 mg/ml) or in Ethanol (up to 15 mg/ml)
• PKA: 9.72±0.30(Predicted)
• Stability: Stable for 2 years from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months.
• CAS DataBase Reference: Ezetimibe(CAS DataBase Reference)
• NIST Chemistry Reference: Ezetimibe(163222-33-1)
• EPA Substance Registry System: Ezetimibe(163222-33-1)

Safety Data

• Statements: 36/37/38
• Safety Statements: 26-36-24/25
• Hazardous Substances Data: 163222-33-1(Hazardous Substances Data)

Usage

Description

Different sources of media describe the Description of 163222-33-1 differently. You can refer to the following data:
1. Ezetimibe is ananti-hyperlipidemic drug used for lowering the plasma cholesterol levels. It is indicated as an adjunctive therapy to diet for the reduction of high-level total-C, LDL-C, and ApoB in patients suffering primary (heterozygous familial and non-familial) hypercholesterolemia. It is also used in combination therapy with HMG-CoA reductase inhibitors.Ezetimibe does not inhibit the cholesterol synthesis in the liver, or increase bile acid excretion.It takes effect throughacting at the brush border of the small intestine and inhibiting the absorption of cholesterol, further leading to a decrease in the delivery of intestinal cholesterol to the liver. This causes a reduction of hepatic cholesterol stores and an increase in clearance of blood cholesterol.
2. Ezetimibe is a once-daily orally active cholesterol absorption inhibitor, launched as a hypolipidemic agent. The one-step diastereo- and enantioselective formation of β-lactams starting from commercially available (3S)-hydroxy-y-lactone is the key point of the asymmetric synthesis of ezetimibe. The 2-azetidinone class was initially designed as acylcoenzyme A: cholesterol acyltransferase (ACAT) inhibitors but experimental data suggest that this compound acts in the intestinal wall to inhibit cholesterol through a novel mechanism with an as yet undiscovered target. Orally administered ezetimibe inhibited increases in plasma cholesterol in four cholesterol-fed animals species (hamster, rats, dogs and rhesus monkeys). In rats cannulated in the intestine and bile duct, [3H]-ezetimibe inhibited cholesterol absorption by more than 95%. In cholesterol-fed LDL receptor+apoE knockout mice, treatment with ezetimibe reduced atherosclerotic lesion cross sectional area by 48% in the aorta and 20% in the carotid artery. Moreover, the plasma cholesterol levels were reduced and the progression of lesions was inhibited. Ezetimibe is highly protein bound and is metabolized by the liver to its glucuronide metabolite, which represents 80-90% of circulating ezetimibe. About 90% of ezetimibe and/or the glucuronide metabolite are excreted in the feces and 10% in the urine. The parent compound and its glucuronide metabolite undergo enterohepatic recirculation; in consequence, the drug is slowly eliminated. In hypercholesterolemic patients, ezetimibe (10 mglday, 12 weeks) reduced LDL cholesterol by 18% and total cholesterol by 12%, with a similar safety profile to placebo. Co-administration of ezetimibe with statins or fenofibrate lowered LDL cholesterol levels more than either monotherapy. Ezetimibe was well tolerated and interaction studies provided evidence that ezetimibe had no significant effect on the activity of major CYP450 drug-metabolizing enzymes. Moreover, no pharmacokinetic/pharmacodynamic interactions were seen between ezetimibe and statins and others frequently administered drugs. .

Indications and Usage

Ezetimibe is a new form of selective cholesterol absorption inhibitor developed in a collaboration between Schering-Plough Co. and Merck Co. This drug is the first cholesterol absorption selective inhibitor to be approved for sale by the American FDA. Its commercial name is Ezetrol. This drug can be used alone or in combination with HMG-CoA reductase inhibitors (statins) to treat primary (heterozygous familial and non-familial) hypercholesterolemia, homozygous familial hypercholesterolemia (HoFH), homozygous viremia (or phytosterolemia).

Mechanisms of Action

Ezetimibe’s mechanisms of action are different from those of other lipid-lowering drugs (such as statins, cholic acid chelating agents, phenoxy acid derivatives, and plant sterols). This drug binds with the surface proteins on the brush border membrane vesicles of the small intestine (relative molecular mass 145x10^3) to inhibit the small intestine’s absorption of cholesterol in food and bile, thus decreasing the cholesterol content in serum and the liver. Ezetimibe is different from bile acid sequestrants because it does not affect the absorption of cholesterol esters, other steroids (such as bezoar and cholic acid), three triacylglycerol, and fat-soluble vitamins. Its effects are unrelated to whether or not acetyl coenzyme A- cholesterol acetyltransferase (ACAT) is inhibited or whether or not the LDL receptor (scavenger receptor) is expressed. After Ezetimibe is absorbed and binds with glucuronic acid in the liver, it undergoes enterohepatic circulation and almost exclusively targets small intestine mucosa cells.

References

Different sources of media describe the References of 163222-33-1 differently. You can refer to the following data:
1. https://en.wikipedia.org/wiki/Ezetimibe https://pubchem.ncbi.nlm.nih.gov/compound/Ezetimibe#section=Top https://www.drugbank.ca/drugs/DB00973 Davidson, Michael H, et al. "Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia ☆." Journal of the American College of Cardiology 40.12(2002):2125. Sudhop, T, et al. "Inhibition of intestinal cholesterol absorption by ezetimibe in humans. " Circulation 106.15(2002):1943-8.
2. 1) Wang?et al. (2007),?Regulation of intestinal cholesterol absorption; Annu. Rev. Physiol.,?69?221 2) Garcia-Calvo?et al. (2005),?The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1); Proc. Natl. Acad. Sci. USA,?102?8132 3) Osuna-Ramos?et al.?(2018),?Ezetimibe inhibits dengue virus infection in Huh-7 cells by blocking the cholesterol transporter Niemann-Pick C1-like 1 receptor; Regulat. Curr. Opin. Cell Biol.,?160?151 4) Kim?et al.?(2017),?Ezetimibe ameliorates steatohepatitis via AMP activated protein kinase-TFEB-mediated activation of autophagy and NLRP3 inflammasome inhibition; Autophagy,?13?1767

Chemical Properties

White Solid

Originator

Schering-Plough (USA)

Uses

Different sources of media describe the Uses of 163222-33-1 differently. You can refer to the following data:
1. An antihyperlipoproteinemic. A Cholesterol absorption inhibitor
2. antibacterial
3. A cholesterol transport inhibitor that binds to NPC1L1
4. For use as adjunctive therapy to diet for the reduction of elevated total-C, LDL-C, and Apo B in patients with primary (heterozygous familial and non-familial) hypercholesterolemia.
5. Ezetimibe (9) was approved as the first hypolipidemic drug to act by blocking the absorption of dietary cholesterol. This drug was discovered by Schering-Plough and is codeveloped and co-marketed by Merck and Schering-Plough for the treatment of hypercholesterolemia and also two less common forms of hyperlipidemia: homozygous familial hypercholesterolemia and homozygous sitosterolemia.

Brand name

Zetia (Merck/Schering-Pough);Ezetrol.

Biological Functions

Ezetimibe lowers plasma cholesterol levels by inhibiting the absorption of cholesterol at the brush border of the small intestine. Specifically, it has been proposed to bind to a specific transport protein located in the wall of the small intestine, resulting in a reduction of cholesterol transport and absorption. Ezetimibe appears to be selective in its actions in that it does not interfere with the absorption of triglycerides, lipid-soluble vitamins or other nutrients. The decreased absorption of cholesterol eventually leads to enhanced receptor-mediated LDL uptake similar to that seen with bile acid sequestrants and HMGRIs. When used as monotherapy, the decreased absorption of cholesterol causes a compensatory increase in cholesterol biosynthesis. This is similar to that described for bile acid sequestrants and is insufficient to override the overall LDL lowering effects of ezetimibe.

General Description

Ezetimibe, (3R,4S)-1-(4-fluorophenyl)-3-((3S)-3-(4-fluorophenyl)-3-hydroxypropyl)-4-(4-hydroxyphenyl)-2-azetidinone (Zetia), is an antihyperlipidemicagent that has usefulness in lowering cholesterol levels. Itacts by decreasing cholesterol absorption in the intestine byblocking the absorption of the sterol at the Brush boarder.Specifically, the -lactam binds to the Niemann-Pick C1-Like 1 (NPC1L1) protein on the gastrointestinal tract that isresponsible for cholesterol absorption. Although it may beused alone, it is marketed as a combination product withsimvastatin under the trade name Vytorin.

Biochem/physiol Actions

Ezetimibe is a non statin drug that reduces intestinal cholesterol absorption. In addition, it also has an ability to reduce the risk of cardiovascular events in patients who had had an acute coronary syndrome and whose low-density lipoprotein (LDL) cholesterol values were within guideline recommendations.

Pharmacokinetics

Ezetimibe is administered orally; however, its absolute bioavailability cannot be determined because of its aqueous insolubility and the lack of an injectable formulation. Based on area under the curve values, the oral absorption ranges from 35 to 60%. Mean peak concentrations of the active glucuronidated metabolite are reached within 1 to 2 hours. Both ezetimibe and its glucuronide conjugate are extensively bound (>90%) to plasma proteins. The relative plasma concentrations of ezetimibe and its glucuronide conjugate range from 10 to 20% and from 80 to 90%, respectively. Both compounds have a long half-life of approximately 22 hours. The coadministration of food with ezetimibe has no effect on the extent of absorption.

Clinical Use

Ezetimibe is indicated as monotherapy or in combination with an HMGRI for the reduction of elevated total cholesterol, LDL cholesterol, and apoB in patients with primary (heterozygous familial and nonfamilial) hypercholesterolemia. When used as monotherapy, ezetimibe reduces LDL cholesterol by approximately 18%. When used in combination therapy with an HMGRI, LDL levels are reduced by 25 to 65% depending on the dose of the HMGRI inhibitor. Ezetimibe also is indicated for homozygous familial hypercholesterolemia in combination with either atorvastatin or simvastatin and for homozygous familial sitosterolemia. All indications are for patients who have not responded to diet, exercise, and other nonpharmacological methods.

Side effects

Ezetimibe generally is well tolerated. The most common adverse effects are listed above. Whenever ezetimibe is used in combination with an HMGRI, the incidence of myopathy or rhabdomyolysis does not increase above that seen with HMGRI monotherapy.

Synthesis

The synthesis of ezetimibe (9) begins with the one-step diastereoselective and practical synthesis of the trans β- lactam from commercially available (S)-3-hydroxy-γ-lactone (92). Lactam 95 was obtained by generation of a dianion of lactone 92 with LDA in THF followed by addition of the imine and N,N’-dimethylpropyleneurea (DMPU) to give predominately adduct 93 (93:94 = 79:21). However, intermediate 93 and 94 did not cyclize to their respective lactams due to formation of stable lithium aggregates.Addition of lithium chloride/DMF was employed to cyclize the intermediates into trans-lactam 95 as the major product (trans:cis = 95:5) in a one-pot process from 92 in 64% yield. The 95:5 ratio of compound 95 was oxidatively cleaved with NaIO4 to give aldehyde 96. Mukaiyama aldol condensation was adopted to elaborate the 4-fluorophenylpropyl side chain to give alcohol 98. Without isolation, the reaction mixture was subjected to dehydration using p-TSA to give enone 99 in 75% yield from compound 96. Reduction of the double bond in 99 with Wilkinson’s catalyst yielded ketone 100, which was subjected to the highly enantioselective CBS reduction to give alcohol 101 with a 98:2 selectivity of S:R at the benzylic position. Catalytic hydrogenation of compound 101 gave ezetimibe (9) in 79% yield. Alternatively, a palladium-catalyzed double reduction in EtOAc/MeOH of both the double bond and the benzyl protecting group in enone 99 produced free phenol 107 in 90% yield. A three-step one-pot procedure was subsequently developed to transform 107 into ezetimibe (9) in 79% yield. That is, free phenol 107 was protected in situ as its TMS ether using BSU followed by a highly selective CBS reduction of the ketone group to give the desired alcohol in 97% ee. The TMS group was removed during acidic workup to give ezetimibe (9). A more convergent approach to this drug was also developed by preparing the (S)-hydroxy side chain before the ring construction. Therefore, p-fluorobenzoylbutyric acid (102) was reacted with pivaloyl chloride and the acid chloride thus obtained was acylated with chiral auxiliary 103 to give the corresponding amide. The ketone group in the amide was reduced with (R)-MeCBS/BH3-THF (104) in the presence of p-TSA to give desired alcohol 105 in high yield (99%) and stereoselectivity (96 % d.e.). Chiral alcohol 105 was then mixed with the imine in the presence of TMSCl and DIPEA to protect the alcohols as TMS ethers. In the same pot, TiCl4 was added to catalyze the condensation reaction and gave compound 106 in 65% yield. Compound 106 was reacted with TBAF and a fluoridecatalyzed cyclization took place to give the corresponding lactam. Finally, the TMS protecting group was removed under acidic conditions to give ezetimibe (9) in 91% yield over two steps.

Drug interactions

Potentially hazardous interactions with other drugs Ciclosporin: concentration of both drugs possibly increased. Lipid lowering agents: avoid with fibrates; concentration of rosuvastatin increased - reduce rosuvastatin dose.

Metabolism

Following oral administration, ezetimibe is rapidly and extensively metabolized in the intestinal wall and the liver to its active metabolite, a corresponding phenol glucuronide. This glucuronide is reexcreted in the bile back to its active site. A small amount (<5%) of ezetimibe undergoes oxidation to covert the benzylic hydroxyl group to a ketone; however, ezetimibe does not appear to exert any significant effect on the activity of CYP450 enzymes.

InChI:InChI=1/C24H21F2NO3/c25-17-5-1-15(2-6-17)22(29)14-13-21-23(16-3-11-20(28)12-4-16)27(24(21)30)19-9-7-18(26)8-10-19/h1-12,21-23,28-29H,13-14H2

Synthetic route

(3R,4S)-1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3(S)-hydroxypropyl]-4-(4-benzyloxyphenyl)-2-azetidinone (163222-32-0) → ezetemibe (163222-33-1)

Conditions	Yield
With 10 wt% Pd(OH)2 on carbon; hydrogen In methanol; cyclohexane at 70℃; under 760.051 Torr; for 3h;	99%
With 5%-palladium/activated carbon; hydrogen In tetrahydrofuran; ethanol at 50 - 55℃; under 37.5038 - 75.0075 Torr;	90.3%
With palladium 10% on activated carbon; ammonium formate; acetic acid for 6h; Reflux;	90%

1-(4-fluorophenyl)-3(R)-[3-(4-fluorophenyl)-3(S)-hydroxypropyl]-4(S)-(4-hydroxyphenyl)-2-azetidinone hydrate (873205-85-7) → ezetemibe (163222-33-1)

Conditions	Yield
In n-heptane; tert-butyl methyl ether at 20℃; Product distribution / selectivity; Heating / reflux;	99%
In Isopropyl acetate at 20℃; Product distribution / selectivity; Heating / reflux;
With acetic acid at 20℃; Product distribution / selectivity; Heating / reflux;

(3R,4S)-1-(4-fluorophenyl)-3-((S)-3-(4-fluorophenyl)-3-(trimethylsilyloxy)propanyl)-4-(4-(trimethylsiloxy)phenyl)azetidinone → ezetemibe (163222-33-1)

Conditions	Yield
With sulfuric acid In water; isopropyl alcohol at 20 - 25℃; for 1h;	95%
With perchloric acid at 40℃; for 3h; Temperature; Solvent;	92%
With sulfuric acid In water; isopropyl alcohol at 20℃; for 1h;	91.5%

C30H35F2NO3Si → ezetemibe (163222-33-1)

Conditions	Yield
With pyridine hydrofluoride In tetrahydrofuran; pyridine at 20℃; for 24h;	93%

4-((2S,3R)-1-(4-fluorophenyl)-3-((S)-3-(4-fluorophenyl)-3-hydroxypropyl)-4-oxoazetidin-2-yl)phenyl pivalate (1232148-26-3) → ezetemibe (163222-33-1)

Conditions	Yield
Stage #1: 4-((2S,3R)-1-(4-fluorophenyl)-3-((S)-3-(4-fluorophenyl)-3-hydroxypropyl)-4-oxoazetidin-2-yl)phenyl pivalate With sodium hydroxide In tetrahydrofuran; methanol at -15℃; Stage #2: With hydrogenchloride; water In ethyl acetate	92%

C39H45ClF2N2O5Si2 → ezetemibe (163222-33-1)

Conditions	Yield
With N,O-bis-(trimethylsilyl)-acetamide; tetrabutyl ammonium fluoride In tert-butyl methyl ether at 20℃; for 0.25h;	91%

[14C]-Sch 57871 (191330-56-0) → ezetemibe (163222-33-1)

Conditions	Yield
With dimethylsulfide borane complex; trifluoroacetic anhydride; (3aR)-1-methyl-3,3-diphenyl-tetrahydro-pyrrolo[1,2-c][1,3,2]oxazaborole In dichloromethane; toluene at -25 - -20℃; for 3h; Inert atmosphere;	90%
With glucose dehydrogenase; alpha-D-glucopyranose; NADP; KRED-128 In water; isopropyl alcohol at 35℃; for 1.5h; pH=7; Product distribution / selectivity; Phosphate buffer;	89.26%
With glucose dehydrogenase; potassium phosphate; alpha-D-glucopyranose; DL-dithiothreitol; NADP; magnesium sulfate; KRED-118 In methanol; water at 30℃; pH=7.0; Product distribution / selectivity;	87.59%

C28H29F2NO5 → ezetemibe (163222-33-1)

Conditions	Yield
With hydrogen bromide In isopropyl alcohol at 20℃; for 4h;	87%

(3R,4S)-1-(4-fluorophenyl)-3-((S)-3-(4-fluorophenyl)-3-hydroxypropyl)-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)azetidin-2-one (1004520-48-2) → ezetemibe (163222-33-1)

Conditions	Yield
With dihydrogen peroxide In acetic acid at 20℃; for 2h; Time;	86.23%
With dihydrogen peroxide In water; isopropyl alcohol at 20℃; for 0.5h;

(3R,4S)-1-(4-fluorophenyl)-[3(S)-hydroxy-3-(4-fluorophenyl)propyl]-[4-(phenylmethoxy)phenyl]-2-azetidinone → ezetemibe (163222-33-1)

Conditions	Yield
With palladium on activated charcoal; hydrogen; acetic acid In ethanol at 25℃; for 4h; pH=3;	85.4%

C36H49F2NO3Si2 → ezetemibe (163222-33-1)

Conditions	Yield
With hydrogen fluoride In ethanol at 0 - 10℃; Inert atmosphere;	80.6%

benzyl (4-((2S,3R)-1-(4-fluorophenyl)-3-((S)-3-(4-fluorophenyl)-3-hydroxypropyl)-4-oxoazetidin-2-yl)phenyl) carbonate (1159183-24-0) → ezetemibe (163222-33-1)

Conditions	Yield
With hydrogen; palladium 10% on activated carbon In methanol under 760.051 Torr; for 23h; Product distribution / selectivity;	76%

C42H61F2NO3Si2 → ezetemibe (163222-33-1)

Conditions	Yield
With trimethyl(benzyl)ammonium fluoride In propan-1-ol at 20 - 30℃; Inert atmosphere;	75.1%

C34H35F2NO3Si → ezetemibe (163222-33-1)

Conditions	Yield
Stage #1: C34H35F2NO3Si With sulfuric acid In isopropyl alcohol at 20℃; for 1h; Stage #2: With palladium 10% on activated carbon; hydrogen; ammonium formate In methanol for 2h; Inert atmosphere;	75%

C43H35F2NO3 (1042722-68-8) → ezetemibe (163222-33-1)

Conditions	Yield
With hydrogen; 3% Pd/C In methanol at 20℃; for 18h; Product distribution / selectivity;	73.3%

[14C]-Sch 57871 (191330-56-0) → ezetemibe (163222-33-1) + (3R,4S)-1-(4-fluorophenyl)-3-[(3R)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-azetidin-2-one (163380-16-3)

Conditions	Yield
With sodium tetrahydroborate; iodine; (3aR)-1-methyl-3,3-diphenyl-tetrahydro-pyrrolo[1,2-c][1,3,2]oxazaborole In tetrahydrofuran; dichloromethane; toluene at -8 - 0℃; for 4h; Corey-Bakshi-Shibata Reduction; Inert atmosphere; stereoselective reaction;	A 55.4% B n/a
With hydrogen; palladium 10% on activated carbon In ethanol under 3102.97 Torr; for 16h;
With Rhodococcus fascians MO22 cells at 35℃; pH=7; Microbiological reaction; aq. phosphate buffer; optical yield given as %de; diastereoselective reaction;

(3R,4S)-4-(4-(trimethylsilyloxy)phenyl)-1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-oxopropyl]azetidin-2-one (954109-26-3) → ezetemibe (163222-33-1)

Conditions

Yield

Stage #1: (3R,4S)-4-(4-(trimethylsilyloxy)phenyl)-1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-oxopropyl]azetidin-2-one With methanesulfonic acid; dimethylsulfide borane complex; (3aR)-1-methyl-3,3-diphenyl-tetrahydro-pyrrolo[1,2-c][1,3,2]oxazaborole In tetrahydrofuran; methanol; toluene at -25 - 25℃; for 2.5 - 2.75h; Stage #2: With hydrogenchloride; water In tetrahydrofuran; methanol; toluene at 0℃; for 0.5h; Product distribution / selectivity;

[14C]-Sch 57871 (191330-56-0) → (3R,4R)-1-(4-fluorophenyl)-3-((S)-3-(4-fluorophenyl)-3-hydroxypropyl)-4-(4-hydroxyphenyl)azetidin-2-one + ezetemibe (163222-33-1)

Conditions	Yield
With formic acid; triethylamine; (1S,2S)-N-methanesulfonyl-1,2-diphenylethane-1,2-diamine; [ruthenium(II)(η6-1-methyl-4-isopropyl-benzene)(chloride)(μ-chloride)]2 In tert-butyl methyl ether at 65℃; for 17h; Product distribution / selectivity;	A n/a B n/a
With formic acid; triethylamine; dichloro(benzene)ruthenium(II) dimer; (1S,2S)-N-methanesulfonyl-1,2-diphenylethane-1,2-diamine In tert-butyl methyl ether at 65℃; for 17h; Product distribution / selectivity;	A n/a B n/a
With formic acid; triethylamine; dichloro(mesitylene)ruthenium(II) dimer; N-((1S,2S)-2-amino-1,2-diphenylethyl)-1,1,1-trifluoromethanesulfonamide In tert-butyl methyl ether at 65℃; for 17h; Product distribution / selectivity;	A n/a B n/a

(3R,4S)-4-[4-(benzyloxy)phenyl]-1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-oxopropyl]azetidin-2-one (190595-65-4) → ezetemibe (163222-33-1)

Conditions	Yield
Multi-step reaction with 2 steps 1: 70 percent / CBS; BH3-Me2S / toluene; CH2Cl2 / 2 h / -20 °C 2: 79 percent / ammonium formate; HOAc / Pd-C / methanol / 3 h / 45 - 55 °C / pH 3 - 5 View Scheme
Multi-step reaction with 2 steps 1: BH3*Me2S / tetrahydrofuran / 3 h / 22 °C 2: H2 / 10percent Pd/C / ethanol / 16 h / 3102.9 Torr View Scheme
Multi-step reaction with 2 steps 1: dimethylsulfide borane complex; (3aR)-1-methyl-3,3-diphenyl-tetrahydro-pyrrolo[1,2-c][1,3,2]oxazaborole / dichloromethane; tetrahydrofuran / 5 h / 0 °C 2: palladium on activated charcoal; hydrogen / methanol / 6 h / 20 °C / 3800.26 Torr View Scheme
Multi-step reaction with 2 steps 1: dimethylsulfide borane complex; (3aR)-1-methyl-3,3-diphenyl-tetrahydro-pyrrolo[1,2-c][1,3,2]oxazaborole / tetrahydrofuran; dichloromethane / 5 h / 0 °C 2: palladium on activated charcoal; hydrogen / methanol / 6 h / 20 °C / 3800.26 Torr View Scheme
Multi-step reaction with 2 steps 1: dimethylsulfide borane complex / tetrahydrofuran / 4 h / -10 °C / Inert atmosphere 2: palladium on activated charcoal; formic acid; ammonium formate / isopropyl alcohol / 3 h / 40 °C View Scheme

4-benzyloxybenzylidene-N-(4-fluoro)phenylanisidine (70627-52-0) → ezetemibe (163222-33-1)

Conditions	Yield
Multi-step reaction with 6 steps 1: 64 percent / LDA; DMPU; LiCl / dimethylformamide; tetrahydrofuran / 18 h / -30 - -25 °C 2: 90 percent / NaIO4 / acetonitrile; H2O / 2 h / 20 °C 3: BF3 etherate / toluene / 0.08 h / -30 °C 4: 99 g / p-toluenesulfonic acid monohydrate; molecular sieves / toluene / 4 h / 40 - 50 °C 5: 90 percent / hydrogen / 10 percent Pd/C / methanol; ethyl acetate / 3 h / 1551.44 Torr 6: 79 percent / bistrimethylsilylurea; BH3-Me2S / CH2Cl2 / 5 h / -20 - -15 °C View Scheme
Multi-step reaction with 7 steps 1: 64 percent / LDA; DMPU; LiCl / dimethylformamide; tetrahydrofuran / 18 h / -30 - -25 °C 2: 90 percent / NaIO4 / acetonitrile; H2O / 2 h / 20 °C 3: BF3 etherate / toluene / 0.08 h / -30 °C 4: 99 g / p-toluenesulfonic acid monohydrate; molecular sieves / toluene / 4 h / 40 - 50 °C 5: 71 percent / (PPh3)3RhCl; hydrogen / CH2Cl2 / 18 h / 3102.89 Torr 6: 70 percent / CBS; BH3-Me2S / toluene; CH2Cl2 / 2 h / -20 °C 7: 79 percent / ammonium formate; HOAc / Pd-C / methanol / 3 h / 45 - 55 °C / pH 3 - 5 View Scheme
Multi-step reaction with 5 steps 1: N-ethyl-N,N-diisopropylamine; titanium(IV) isopropylate; titanium tetrachloride / dichloromethane / 3 h / -5 °C 2: N,O-Bis(trimethylsilyl)acetamide; tetrabutyl ammonium fluoride / toluene / 48 h / Reflux 3: formic acid / dichloromethane / 12 h / Reflux 4: dimethyl sulfide borane / dichloromethane; toluene; tetrahydrofuran / 12 h / 15 °C 5: acetic acid; ammonium formate; palladium 10% on activated carbon / 6 h / Reflux View Scheme
Multi-step reaction with 3 steps 1.1: N-ethyl-N,N-diisopropylamine; titanium(IV) isopropylate; titanium tetrachloride / dichloromethane / 5 h / -30 - -20 °C 2.1: tetrabutyl ammonium fluoride / toluene / 3 h / 60 °C 3.1: sulfuric acid / isopropyl alcohol / 1 h / 20 °C 3.2: 2 h / Inert atmosphere View Scheme
Multi-step reaction with 3 steps 1: N,O-bis-(trimethylsilyl)-acetamide; tetrabutyl ammonium fluoride / toluene / 60 °C 2: dimethylsulfide borane complex / dichloromethane; toluene / 3 h / -5 - 0 °C / Inert atmosphere 3: palladium 10% on activated carbon; hydrogen / methanol; tetrahydrofuran / 2 h View Scheme

(2S,3S)-2-(4-(benzyloxy)phenyl)-1-(4-fluorophenyl)-4-oxazetidine-3-carbaldehyde (221349-58-2) → ezetemibe (163222-33-1)

Conditions	Yield
Multi-step reaction with 4 steps 1: BF3 etherate / toluene / 0.08 h / -30 °C 2: 99 g / p-toluenesulfonic acid monohydrate; molecular sieves / toluene / 4 h / 40 - 50 °C 3: 90 percent / hydrogen / 10 percent Pd/C / methanol; ethyl acetate / 3 h / 1551.44 Torr 4: 79 percent / bistrimethylsilylurea; BH3-Me2S / CH2Cl2 / 5 h / -20 - -15 °C View Scheme
Multi-step reaction with 5 steps 1: BF3 etherate / toluene / 0.08 h / -30 °C 2: 99 g / p-toluenesulfonic acid monohydrate; molecular sieves / toluene / 4 h / 40 - 50 °C 3: 71 percent / (PPh3)3RhCl; hydrogen / CH2Cl2 / 18 h / 3102.89 Torr 4: 70 percent / CBS; BH3-Me2S / toluene; CH2Cl2 / 2 h / -20 °C 5: 79 percent / ammonium formate; HOAc / Pd-C / methanol / 3 h / 45 - 55 °C / pH 3 - 5 View Scheme

(3S,4S)-4-(4-Benzyloxy-phenyl)-3-((S)-1,2-dihydroxy-ethyl)-1-(4-fluoro-phenyl)-azetidin-2-one (221349-56-0) → ezetemibe (163222-33-1)

Conditions	Yield
Multi-step reaction with 5 steps 1: 90 percent / NaIO4 / acetonitrile; H2O / 2 h / 20 °C 2: BF3 etherate / toluene / 0.08 h / -30 °C 3: 99 g / p-toluenesulfonic acid monohydrate; molecular sieves / toluene / 4 h / 40 - 50 °C 4: 90 percent / hydrogen / 10 percent Pd/C / methanol; ethyl acetate / 3 h / 1551.44 Torr 5: 79 percent / bistrimethylsilylurea; BH3-Me2S / CH2Cl2 / 5 h / -20 - -15 °C View Scheme
Multi-step reaction with 6 steps 1: 90 percent / NaIO4 / acetonitrile; H2O / 2 h / 20 °C 2: BF3 etherate / toluene / 0.08 h / -30 °C 3: 99 g / p-toluenesulfonic acid monohydrate; molecular sieves / toluene / 4 h / 40 - 50 °C 4: 71 percent / (PPh3)3RhCl; hydrogen / CH2Cl2 / 18 h / 3102.89 Torr 5: 70 percent / CBS; BH3-Me2S / toluene; CH2Cl2 / 2 h / -20 °C 6: 79 percent / ammonium formate; HOAc / Pd-C / methanol / 3 h / 45 - 55 °C / pH 3 - 5 View Scheme

lithium; 1-(4-fluoro-phenyl)-ethenolate → ezetemibe (163222-33-1)

Conditions	Yield
Multi-step reaction with 4 steps 1: BF3 etherate / toluene / 0.08 h / -30 °C 2: 99 g / p-toluenesulfonic acid monohydrate; molecular sieves / toluene / 4 h / 40 - 50 °C 3: 90 percent / hydrogen / 10 percent Pd/C / methanol; ethyl acetate / 3 h / 1551.44 Torr 4: 79 percent / bistrimethylsilylurea; BH3-Me2S / CH2Cl2 / 5 h / -20 - -15 °C View Scheme
Multi-step reaction with 5 steps 1: BF3 etherate / toluene / 0.08 h / -30 °C 2: 99 g / p-toluenesulfonic acid monohydrate; molecular sieves / toluene / 4 h / 40 - 50 °C 3: 71 percent / (PPh3)3RhCl; hydrogen / CH2Cl2 / 18 h / 3102.89 Torr 4: 70 percent / CBS; BH3-Me2S / toluene; CH2Cl2 / 2 h / -20 °C 5: 79 percent / ammonium formate; HOAc / Pd-C / methanol / 3 h / 45 - 55 °C / pH 3 - 5 View Scheme

(3R,4S)-4-(4-Benzyloxy-phenyl)-1-(4-fluoro-phenyl)-3-[(E)-3-(4-fluoro-phenyl)-3-oxo-propenyl]-azetidin-2-one (221349-60-6) → ezetemibe (163222-33-1)

Conditions	Yield
Multi-step reaction with 2 steps 1: 90 percent / hydrogen / 10 percent Pd/C / methanol; ethyl acetate / 3 h / 1551.44 Torr 2: 79 percent / bistrimethylsilylurea; BH3-Me2S / CH2Cl2 / 5 h / -20 - -15 °C View Scheme
Multi-step reaction with 3 steps 1: 71 percent / (PPh3)3RhCl; hydrogen / CH2Cl2 / 18 h / 3102.89 Torr 2: 70 percent / CBS; BH3-Me2S / toluene; CH2Cl2 / 2 h / -20 °C 3: 79 percent / ammonium formate; HOAc / Pd-C / methanol / 3 h / 45 - 55 °C / pH 3 - 5 View Scheme

(3S,4S)-4-(4-Benzyloxy-phenyl)-1-(4-fluoro-phenyl)-3-[3-(4-fluoro-phenyl)-1-hydroxy-3-oxo-propyl]-azetidin-2-one (231301-00-1) → ezetemibe (163222-33-1)

Conditions	Yield
Multi-step reaction with 3 steps 1: 99 g / p-toluenesulfonic acid monohydrate; molecular sieves / toluene / 4 h / 40 - 50 °C 2: 90 percent / hydrogen / 10 percent Pd/C / methanol; ethyl acetate / 3 h / 1551.44 Torr 3: 79 percent / bistrimethylsilylurea; BH3-Me2S / CH2Cl2 / 5 h / -20 - -15 °C View Scheme
Multi-step reaction with 4 steps 1: 99 g / p-toluenesulfonic acid monohydrate; molecular sieves / toluene / 4 h / 40 - 50 °C 2: 71 percent / (PPh3)3RhCl; hydrogen / CH2Cl2 / 18 h / 3102.89 Torr 3: 70 percent / CBS; BH3-Me2S / toluene; CH2Cl2 / 2 h / -20 °C 4: 79 percent / ammonium formate; HOAc / Pd-C / methanol / 3 h / 45 - 55 °C / pH 3 - 5 View Scheme

(Z)-1-(4-(benzyloxy)phenyl)-N-(4-fluorophenyl)methaneimine (219653-96-0) → ezetemibe (163222-33-1)

Conditions	Yield
Multi-step reaction with 6 steps 1: (nBu)3N / heptane; toluene / 80 - 90 °C 2: LiOH*H2O / methanol / 2 h 3: oxalyl chloride / CH2Cl2 / 16 h / 22 °C 4: (Ph3P)4Pd / tetrahydrofuran / 1 h / 10 °C 5: BH3*Me2S / tetrahydrofuran / 3 h / 22 °C 6: H2 / 10percent Pd/C / ethanol / 16 h / 3102.9 Torr View Scheme

(3R,4S)-1-(4-fluorophenyl)-3-(3-hydroxy-3-oxopropyl)-4-(4-benzyloxyphenyl)-2-azetidinone (204589-82-2) → ezetemibe (163222-33-1)

Conditions	Yield
Multi-step reaction with 4 steps 1: oxalyl chloride / CH2Cl2 / 16 h / 22 °C 2: (Ph3P)4Pd / tetrahydrofuran / 1 h / 10 °C 3: BH3*Me2S / tetrahydrofuran / 3 h / 22 °C 4: H2 / 10percent Pd/C / ethanol / 16 h / 3102.9 Torr View Scheme

3-((3R,4S)-1-(4-fluorophenyl)-2-oxo-4-(4-(benzyloxy)phenyl)azetidin-3-yl)propionic acid chloride (204589-84-4) → ezetemibe (163222-33-1)

Conditions	Yield
Multi-step reaction with 3 steps 1: (Ph3P)4Pd / tetrahydrofuran / 1 h / 10 °C 2: BH3*Me2S / tetrahydrofuran / 3 h / 22 °C 3: H2 / 10percent Pd/C / ethanol / 16 h / 3102.9 Torr View Scheme

methyl 3-((2S,3R)-2-(4-(benzyloxy)phenyl)-1-(4-fluorophenyl)-4-oxoazetidin-3-yl)propanoate (204589-80-0) → ezetemibe (163222-33-1)

Conditions	Yield
Multi-step reaction with 5 steps 1: LiOH*H2O / methanol / 2 h 2: oxalyl chloride / CH2Cl2 / 16 h / 22 °C 3: (Ph3P)4Pd / tetrahydrofuran / 1 h / 10 °C 4: BH3*Me2S / tetrahydrofuran / 3 h / 22 °C 5: H2 / 10percent Pd/C / ethanol / 16 h / 3102.9 Torr View Scheme
Multi-step reaction with 4 steps 1.1: diethyl aluminiumcholoride / toluene / -12 - 20 °C / Inert atmosphere 2.1: magnesium / tetrahydrofuran / 1 h / 40 - 50 °C / Inert atmosphere 2.2: 1 h / -5 - 0 °C 3.1: [(S,S)-teth-TsDpen RuCl]; triethylamine; formic acid / ethylbenzene / 24 h / 35 - 40 °C / Inert atmosphere 4.1: 5%-palladium/activated carbon; hydrogen / tetrahydrofuran; ethanol / 50 - 55 °C / 37.5 - 75.01 Torr View Scheme

acetic anhydride (108-24-7) + ezetemibe (163222-33-1) → 4(S)-(4-acetyloxyphenyl)-3(R)-(3(S)-acetyloxy-3-(4-fluorophenyl)propyl)-1-(4-fluorophenyl)-2-azetidinone (163380-20-9)

Conditions	Yield
With dmap; triethylamine In dichloromethane	100%
With dmap; triethylamine In dichloromethane at 20℃; for 2h;	96%

phenyl trifluoromethanesulfonamide (456-64-4) + ezetemibe (163222-33-1) → (trifluoromethanesulfonyl)ezetimibe (847781-45-7)

Conditions	Yield
With dmap; triethylamine In dichloromethane at 20℃; for 3.5h;	99%
With dmap; triethylamine In dichloromethane at 20℃; for 3.5h;	96%

benzyl bromide (100-39-0) + ezetemibe (163222-33-1) → (3R,4S)-1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3(S)-hydroxypropyl]-4-(4-benzyloxyphenyl)-2-azetidinone (163222-32-0)

Conditions	Yield
With caesium carbonate In N,N-dimethyl-formamide at 20℃; for 3h;	99%

acetic anhydride (108-24-7) + ezetemibe (163222-33-1) → Acetic acid 4-{(2S,3R)-1-(4-fluoro-phenyl)-3-[(S)-3-(4-fluoro-phenyl)-3-hydroxy-propyl]-4-oxo-azetidin-2-yl}-phenyl ester (795306-53-5)

Conditions	Yield
With sodium hydroxide In isopropyl alcohol for 5h;	97%
With sodium hydroxide In water; isopropyl alcohol for 5h;	97%

tert-butyldimethylsilyl chloride (18162-48-6) + ezetemibe (163222-33-1) → 3-[3-(tert-butyl-dimethyl-silanyloxy)-3-(4-fluoro-phenyl)-propyl]-4-[4-(tert-butyl-dimethyl-silanyloxy)-phenyl]-1-(4-fluoro-phenyl)-azetidin-2-one (849799-39-9)

Conditions	Yield
With 1H-imidazole In N,N-dimethyl-formamide for 5h;	97%
With 1H-imidazole In DMF (N,N-dimethyl-formamide) for 5h;	97%

N,N-phenylbistrifluoromethane-sulfonimide (37595-74-7) + ezetemibe (163222-33-1) → (trifluoromethanesulfonyl)ezetimibe (847781-45-7)

Conditions	Yield
With dmap; triethylamine In dichloromethane at 20℃; for 3.5h;	96%
With dmap; triethylamine In dichloromethane at 23℃; for 3h;	95%
With dmap; triethylamine In dichloromethane at 23℃; for 3h;	95%
With dmap; triethylamine In dichloromethane at 20℃; for 3h; Inert atmosphere;	562.7 mg

benzyl chloroformate (501-53-1) + ezetemibe (163222-33-1) → benzyl (4-((2S,3R)-1-(4-fluorophenyl)-3-((S)-3-(4-fluorophenyl)-3-hydroxypropyl)-4-oxoazetidin-2-yl)phenyl) carbonate (1159183-24-0)

Conditions	Yield
With triethylamine In dichloromethane at 0℃; for 0.5h;	92%

Upstream product

• 191330-56-0 [14C]-Sch 57871 
• 272778-13-9 (3R,4S)-1-(4-fluorophenyl)-3-((S)-3-(4-fluorophenyl)-3-(trimethylsilyloxy)propanyl)-4-(4-(trimethylsiloxy)phenyl)azetidinone 
• 204589-80-0 methyl 3-((2S,3R)-2-(4-(benzyloxy)phenyl)-1-(4-fluorophenyl)-4-oxoazetidin-3-yl)propanoate 
• 221349-56-0 (3S,4S)-4-(4-Benzyloxy-phenyl)-3-((S)-1,2-dihydroxy-ethyl)-1-(4-fluoro-phenyl)-azetidin-2-one 
• 221349-58-2 (2S,3S)-2-(4-(benzyloxy)phenyl)-1-(4-fluorophenyl)-4-oxazetidine-3-carbaldehyde 
• 70627-52-0 4-benzyloxybenzylidene-N-(4-fluoro)phenylanisidine 
• 190595-65-4 (3R,4S)-4-[4-(benzyloxy)phenyl]-1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-oxopropyl]azetidin-2-one 
• 954109-26-3 (3R,4S)-4-(4-(trimethylsilyloxy)phenyl)-1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-oxopropyl]azetidin-2-one 
• 163222-32-0 (3R,4S)-1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3(S)-hydroxypropyl]-4-(4-benzyloxyphenyl)-2-azetidinone 
• 870634-36-9 methyl 5S-5-(4-fluorophenyl)-5-hydroxyvalerate 
• 3382-63-6 N-(4-hydroxybenzylidene)-4-fluorobenzenamine 
• 190595-64-3 (3R,4S)-4-(4-(benzyloxy)phenyl)-1-(4-fluorophenyl)-3-((E)-3-(4-fluorophenyl)allyl)azetidin-2-one 
• 405-99-2 para-fluorostyrene 
• 1185883-40-2 C₃₃H₃₀F₂N₂O₅ 

Downstream Products

• 204589-68-4 1-(4-fluorophenyl)-(3R)-[(4-fluorophenyl)-(2E)-propenyl]-(4S)-(4-hydroxyphenyl)-2-azetidinone 
• 795306-53-5 Acetic acid 4-{(2S,3R)-1-(4-fluoro-phenyl)-3-[(S)-3-(4-fluoro-phenyl)-3-hydroxy-propyl]-4-oxo-azetidin-2-yl}-phenyl ester 
• 873205-85-7 1-(4-fluorophenyl)-3(R)-[3-(4-fluorophenyl)-3(S)-hydroxypropyl]-4(S)-(4-hydroxyphenyl)-2-azetidinone hydrate 
• 1004520-48-2 (3R,4S)-1-(4-fluorophenyl)-3-((S)-3-(4-fluorophenyl)-3-hydroxypropyl)-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)azetidin-2-one 

Relevant articles and documents

Preparation method of ezetimibe and intermediate thereof

The invention discloses a preparation method of ezetimibe and an intermediate thereof. The invention provides a preparation method of an ezetimibe intermediate IV. The preparation method comprises thefollowing steps: an ezetimibe intermediate II and an ezetimibe intermediate III are subjected to a cyclization reaction to obtain the ezetimibe intermediate IV in the presence of a trialkylchlorosilane, an organic base, a chiral catalyst and lithium diisopropylamide in an organic solvent, wherein R is methyl, ethyl or propyl. The preparation method is short in route steps, mild in reaction conditions and simple in post-treatment steps, and avoids the connection of a substrate with a chiral group, and the obtained product is high in purity, achieves the standard of bulk drugs, is high in yield, low in production cost, high in atomic utilization rate, and suitable for industrial production.

METHOD OF PREPARING EZETIMIBE AND INTERMEDIATE THEREOF

Disclosed is a method of preparing ezetimibe, including cross-metathesis using a Grubbs 2nd catalyst and deprotection using a Pearlman's catalyst, and an intermediate thereof. The method of preparing ezetimibe is useful as an efficient ezetimibe synthesis technique in pharmaceutical fields using ezetimibe as a raw material.

Preparation method of ezetimibe for treating hyperlipidemia

The invention discloses a preparation method of ezetimibe for treating hyperlipidemia, and belongs to the field of drug synthesizing. The method is characterized in that a compound 2 is treated as theraw material and subjected to four synthesizing steps to prepare ezetimibe 1, wherein the four steps include the step of protection for carbonyl group, cyclizing, carbonyl reduction and hydrogenationdeprotection. Compared with methods in existing documents, the preparation method has the advantages that the use of polluting titanium agents is avoided; the synthesizing steps are decreased; the technology stability is improved; massive production can be performed.